Clinical Trial Update: PF-06671008 Dose Escalation Study in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of PF-06671008 in advanced solid tumors was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• PF-06671008

Snippet

Sponsor: Pfizer | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2020-05-06